• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Prognostic value of the IASLC/ATS/ERS classification and IMP3 expression in lung adenocarcinoma of Chinese cases.IASLC/ATS/ERS分类及IMP3表达在中国肺腺癌病例中的预后价值。
Am J Cancer Res. 2015 Jun 15;5(7):2266-76. eCollection 2015.
2
Impact of proposed IASLC/ATS/ERS classification of lung adenocarcinoma: prognostic subgroups and implications for further revision of staging based on analysis of 514 stage I cases.肺腺癌 IASLC/ATS/ERS 分类的影响:基于 514 例 I 期病例分析的预后亚组和对进一步修订分期的影响。
Mod Pathol. 2011 May;24(5):653-64. doi: 10.1038/modpathol.2010.232. Epub 2011 Jan 21.
3
Prognostic value of the new IASLC/ATS/ERS classification of clinical stage IA lung adenocarcinoma.IASLC/ATS/ERS 新肺腺癌临床分期 IA 分类的预后价值。
Lung Cancer. 2015 Nov;90(2):199-204. doi: 10.1016/j.lungcan.2015.06.022. Epub 2015 Jul 2.
4
Risk of development of brain metastases according to the IASLC/ATS/ERS lung adenocarcinoma classification in locally advanced and metastatic disease.根据 IASLC/ATS/ERS 肺腺癌分类,在局部晚期和转移性疾病中脑转移的发展风险。
Lung Cancer. 2021 May;155:183-190. doi: 10.1016/j.lungcan.2021.01.023. Epub 2021 Jan 27.
5
Prognostic value of the new International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification in stage IB lung adenocarcinoma.国际肺癌研究协会/美国胸科学会/欧洲呼吸学会新分类在ⅠB期肺腺癌中的预后价值
Eur J Surg Oncol. 2015 Oct;41(10):1430-6. doi: 10.1016/j.ejso.2015.06.004. Epub 2015 Jun 23.
6
Expression and prognostic value of GalNAc-T3 in patients with completely resected small (≤2 cm) peripheral lung adenocarcinoma after IASLC/ATS/ERS classification.IASLC/ATS/ERS分类后完全切除的小(≤2cm)周围型肺腺癌患者中GalNAc-T3的表达及预后价值
Onco Targets Ther. 2015 Oct 27;8:3143-52. doi: 10.2147/OTT.S93486. eCollection 2015.
7
Two-gene signature improves the discriminatory power of IASLC/ATS/ERS classification to predict the survival of patients with early-stage lung adenocarcinoma.双基因特征提高了IASLC/ATS/ERS分类对早期肺腺癌患者生存预测的鉴别能力。
Onco Targets Ther. 2016 Jul 25;9:4583-91. doi: 10.2147/OTT.S107272. eCollection 2016.
8
Validation of the IASLC/ATS/ERS lung adenocarcinoma classification for prognosis and association with EGFR and KRAS gene mutations: analysis of 440 Japanese patients.验证 IASLC/ATS/ERS 肺腺癌分类对预后的影响及其与 EGFR 和 KRAS 基因突变的关系:440 例日本患者的分析。
J Thorac Oncol. 2013 Jan;8(1):52-61. doi: 10.1097/JTO.0b013e3182769aa8.
9
Tumor invasiveness as defined by the newly proposed IASLC/ATS/ERS classification has prognostic significance for pathologic stage IA lung adenocarcinoma and can be predicted by radiologic parameters.IASLC/ATS/ERS 新分类定义的肿瘤侵袭性对病理分期为 IA 期肺腺癌具有预后意义,并可通过影像学参数预测。
J Thorac Cardiovasc Surg. 2014 Jan;147(1):54-9. doi: 10.1016/j.jtcvs.2013.08.058. Epub 2013 Oct 13.
10
Prognostic value of the IASLC/ATS/ERS classification in stage I lung adenocarcinoma patients--based on a hospital study in China.IASLC/ATS/ERS 分类在Ⅰ期肺腺癌患者中的预后价值——基于中国医院的研究。
Eur J Surg Oncol. 2013 Nov;39(11):1262-8. doi: 10.1016/j.ejso.2013.08.026. Epub 2013 Sep 11.

引用本文的文献

1
Characterization of novel small non-coding RNAs and their modifications in bladder cancer using an updated small RNA-seq workflow.使用更新的小RNA测序工作流程对膀胱癌中新型小非编码RNA及其修饰进行表征。
Front Mol Biosci. 2022 Jul 18;9:887686. doi: 10.3389/fmolb.2022.887686. eCollection 2022.
2
Circular RNA circ-TNPO3 suppresses metastasis of GC by acting as a protein decoy for IGF2BP3 to regulate the expression of MYC and SNAIL.环状RNA circ-TNPO3通过作为IGF2BP3的蛋白质诱饵来调节MYC和SNAIL的表达,从而抑制胃癌转移。
Mol Ther Nucleic Acids. 2021 Aug 28;26:649-664. doi: 10.1016/j.omtn.2021.08.029. eCollection 2021 Dec 3.
3
IMP3 is upregulated in primary ovarian mucinous carcinoma and promotes tumor progression.IMP3在原发性卵巢黏液性癌中上调并促进肿瘤进展。
Am J Transl Res. 2017 Jul 15;9(7):3387-3398. eCollection 2017.
4
Prognostic value of high IMP3 expression in solid tumors: a meta-analysis.IMP3高表达在实体瘤中的预后价值:一项荟萃分析。
Onco Targets Ther. 2017 Jun 6;10:2849-2863. doi: 10.2147/OTT.S128810. eCollection 2017.
5
Prognostic value of MMP9 activity level in resected stage I B lung adenocarcinoma.MMP9活性水平在I B期肺腺癌切除术后的预后价值
Cancer Med. 2016 Sep;5(9):2323-31. doi: 10.1002/cam4.821. Epub 2016 Jul 25.

本文引用的文献

1
IMP3 expression in gastric cancer: association with clinicopathological features and HER2 status.IMP3在胃癌中的表达:与临床病理特征及HER2状态的关联
J Cancer Res Clin Oncol. 2014 Dec;140(12):2163-8. doi: 10.1007/s00432-014-1850-9. Epub 2014 Oct 17.
2
IMP3 expression is associated with poor survival in cervical squamous cell carcinoma.IMP3表达与宫颈鳞状细胞癌的不良预后相关。
Hum Pathol. 2014 Nov;45(11):2218-24. doi: 10.1016/j.humpath.2014.07.006. Epub 2014 Jul 30.
3
The oncofetal protein IMP3: a useful marker to predict poor clinical outcome in neuroendocrine tumors of the lung.癌胚蛋白 IMP3:预测肺神经内分泌肿瘤不良临床结局的有用标志物。
J Thorac Oncol. 2014 Nov;9(11):1656-61. doi: 10.1097/JTO.0000000000000316.
4
Predictive value of the international association for the study of lung cancer/American Thoracic Society/European Respiratory Society classification of lung adenocarcinoma in tumor recurrence and patient survival.国际肺癌研究协会/美国胸科学会/欧洲呼吸学会肺腺癌分类在肿瘤复发和患者生存中的预测价值。
J Clin Oncol. 2014 Aug 1;32(22):2357-64. doi: 10.1200/JCO.2013.50.1049. Epub 2014 May 5.
5
IMP3 expression is associated with poor outcome and epigenetic deregulation in intrahepatic cholangiocarcinoma.IMP3 表达与肝内胆管癌不良预后和表观遗传失调相关。
Hum Pathol. 2014 Jun;45(6):1184-91. doi: 10.1016/j.humpath.2014.01.016. Epub 2014 Feb 6.
6
IMP3 combined with CD44s, a novel predictor for prognosis of patients with hepatocellular carcinoma.IMP3 联合 CD44s,一种新型预测肝细胞癌患者预后的标志物。
J Cancer Res Clin Oncol. 2014 Jun;140(6):883-93. doi: 10.1007/s00432-014-1639-x. Epub 2014 Mar 20.
7
Prognostic value of tissue and circulating levels of IMP3 in prostate cancer.IMP3 在前列腺癌中组织和循环水平的预后价值。
Int J Cancer. 2014 Oct 1;135(7):1596-604. doi: 10.1002/ijc.28808. Epub 2014 Mar 4.
8
New IASLC/ATS/ERS classification and invasive tumor size are predictive of disease recurrence in stage I lung adenocarcinoma.新的 IASLC/ATS/ERS 分类和侵袭性肿瘤大小可预测 I 期肺腺癌的疾病复发。
J Thorac Oncol. 2013 May;8(5):612-8. doi: 10.1097/JTO.0b013e318287c3eb.
9
Subtyping lung adenocarcinoma according to the novel 2011 IASLC/ATS/ERS classification: correlation with patient prognosis.根据新的 2011 年 IASLC/ATS/ERS 分类对肺腺癌进行亚型分类:与患者预后的相关性。
Thorac Surg Clin. 2013 May;23(2):179-86. doi: 10.1016/j.thorsurg.2013.01.001. Epub 2013 Feb 7.
10
Correlation of mutation status and survival with predominant histologic subtype according to the new IASLC/ATS/ERS lung adenocarcinoma classification in stage III (N2) patients.新 IASLC/ATS/ERS 肺腺癌分类中 III 期(N2)患者主要组织学亚型与突变状态和生存的相关性。
J Thorac Oncol. 2013 Apr;8(4):461-8. doi: 10.1097/JTO.0b013e3182828fb8.

IASLC/ATS/ERS分类及IMP3表达在中国肺腺癌病例中的预后价值。

Prognostic value of the IASLC/ATS/ERS classification and IMP3 expression in lung adenocarcinoma of Chinese cases.

作者信息

Sun Xiangjie, Wei Ping, Shen Chen, Yang Yusi, Wang Yiqin, Li Yuan, Du Xiang

机构信息

Department of Pathology, Fudan University Shanghai Cancer Center Shanghai 200032, China ; Institute of Pathology, Fudan University Shanghai 200032, China ; Institute of Biomedical Sciences, Fudan University Shanghai 200032, China ; Department of Oncology, Shanghai Medical College, Fudan University Shanghai 200032, China.

Department of Pathology, Fudan University Shanghai Cancer Center Shanghai 200032, China ; Institute of Pathology, Fudan University Shanghai 200032, China ; Cancer Institute, Fudan University Shanghai Cancer Center Shanghai 200032, China ; Department of Oncology, Shanghai Medical College, Fudan University Shanghai 200032, China.

出版信息

Am J Cancer Res. 2015 Jun 15;5(7):2266-76. eCollection 2015.

PMID:26328257
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4548338/
Abstract

The IASLC/ATS/ERS classification system was proposed in 2011 to improve the histological subtypes of lung adenocarcinoma, while the prognostic value of the combination of histological predominant subtypes is not consistent. IMP3 is an oncofetal protein which has been proved associated with aggressive tumor behavior in malignancies, but few reports were investigated in lung adenocarcinoma. The aim of this study is to explore the prognostic value of the IASLC/ATS/ERS classification and IMP3 expression in lung adenocarcinoma of Chinese cases. A total of 196 cases were classified according to the IASLC/ATS/ERS classification system and immunohistochemically analyzed by using a monoclonal antibody against IMP3. Univariate survival analysis indicated patients with solid-predominant subtype had shorter disease-free survival (P = 0.003) and overall survival (P = 0.014) compared to those with non-solid predominant subtype. Multivariate survival analysis revealed that solid-predominant subtype could be an independent prognostic factor for disease-free survival (HR: 1.22, 95% CI: 1.05-1.41; P = 0.008). Analysis of IMP3 expression showed that IMP3 was more frequently overexpressed in tumors with advanced pTNM stage (P < 0.001), larger tumor size (P = 0.036), poorer histological differentiation (P < 0.001), lymph node metastasis (P < 0.001), and solid-predominant subtype (P < 0.001). Survival analysis also confirmed that patients in IMP3 high-expression group had both worse disease-free survival (P = 0.039) and overall survival (P = 0.029) than those in IMP3 low-expression group. Our results illustrated that solid-predominant subtype according to the IASLC/ATS/ERS classification is an independent prognostic factor, and IMP3 overexpression is associated with aggressive tumor behavior and poor clinical outcome in lung adenocarcinoma.

摘要

国际肺癌研究协会(IASLC)/美国胸科学会(ATS)/欧洲呼吸学会(ERS)分类系统于2011年提出,旨在改进肺腺癌的组织学亚型,然而组织学主要亚型组合的预后价值并不一致。IMP3是一种癌胚蛋白,已被证明与恶性肿瘤的侵袭性肿瘤行为相关,但在肺腺癌中的报道较少。本研究的目的是探讨IASLC/ATS/ERS分类和IMP3表达在中国肺腺癌病例中的预后价值。根据IASLC/ATS/ERS分类系统对196例病例进行分类,并使用抗IMP3单克隆抗体进行免疫组化分析。单因素生存分析表明,与非实性为主亚型患者相比,实性为主亚型患者的无病生存期(P = 0.003)和总生存期(P = 0.014)较短。多因素生存分析显示,实性为主亚型可能是无病生存期的独立预后因素(HR:1.22,95%CI:1.05 - 1.41;P = 0.008)。IMP3表达分析表明,IMP3在pTNM分期较晚(P < 0.001)、肿瘤体积较大(P = 0.036)、组织学分化较差(P < 0.001)、有淋巴结转移(P < 0.001)和实性为主亚型(P < 0.001)的肿瘤中更频繁地过度表达。生存分析还证实,IMP3高表达组患者的无病生存期(P = 0.039)和总生存期(P = 0.029)均比IMP3低表达组患者差。我们的结果表明,根据IASLC/ATS/ERS分类的实性为主亚型是一个独立的预后因素,IMP3过度表达与肺腺癌的侵袭性肿瘤行为和不良临床结局相关。